Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B.
AffiliationCRC Psychosocial Oncology Group, Department of Oncology, University College London Medical School, UK. I.email@example.com
MetadataShow full item record
AbstractExisting quality of life instruments do not include adequate items to measure the side effects and putative benefits of hormonal treatments given in breast cancer. We report the development and validation of an 18 item endocrine subscale (ES) to accompany a standardised breast cancer quality of life measure, the Functional Assessment of Cancer Therapy (FACT-B). The FACT-ES (FACT-B plus ES) was tested initially on 268 women with breast cancer receiving endocrine treatments. Alpha coefficients for all subscales demonstrated good internal consistency (range alpha = 0.65-0.87). Test-retest reliability of the ES indicated good stability (r = 0.93, p < 0.001). Advanced breast cancer patients' quality of life was high, showing the efficacy of endocrine therapy, but women with primary disease reported better physical, social, and functional well-being and fewer breast cancer concerns. Most frequently reported symptoms were loss of sexual interest (31%), weight gain (25%), and hot flushes (24%). Significant differences were found between treatment groups for hot flushes and vaginal dryness. Two assessments of the instrument's responsiveness to change were made; 32 women in a clinical trial of endocrine therapy and 18 women without breast cancer taking HRT completed the FACT-ES at baseline, 4, 8, and 12 weeks. Trial patients reported significantly more symptoms at 8 and 12 weeks than at baseline. Women taking HRT reported significantly fewer or less severe symptoms than at baseline. In conclusion the FACT-ES has acceptable validity and reliability and is sensitive to clinically significant change, making it suitable for clinical trials of endocrine therapy.
CitationAssessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B. 1999, 55 (2):189-99 Breast Cancer Res. Treat.
JournalBreast Cancer Research and Treatment
- Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial.
- Authors: Fallowfield L, Cella D, Cuzick J, Francis S, Locker G, Howell A
- Issue date: 2004 Nov 1
- Anastrozole and letrozole: an investigation and comparison of quality of life and tolerability.
- Authors: Dixon JM, Renshaw L, Langridge C, Young OE, McHugh M, Williams L, Murray J, Macaskill EJ, McCaig F, Dixon OM, Fallowfield LJ
- Issue date: 2011 Feb
- Health-related quality of life and psychological distress of breast cancer patients after surgery during a phase III randomized trial comparing continuation of tamoxifen with switching to anastrozole after adjuvant tamoxifen for 1-4 years: N-SAS BC 03.
- Authors: Ohsumi S, Shimozuma K, Ohashi Y, Shinji M, Hozumi Y, Mukai H, Takatsuka Y, Aihara T
- Issue date: 2011 May
- Health-related quality of life and psychological distress during neoadjuvant endocrine therapy with letrozole to determine endocrine responsiveness in postmenopausal breast cancer.
- Authors: Taira N, Iwata H, Hasegawa Y, Sakai T, Higaki K, Kihara K, Yamaguchi T, Ohsumi S, Shimozuma K, Ohashi Y
- Issue date: 2014 May
- Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-SAS BC 04).
- Authors: Takei H, Ohsumi S, Shimozuma K, Takehara M, Suemasu K, Ohashi Y, Hozumi Y
- Issue date: 2012 May